WO2010079063A3 - Modulators of the cx3cr1 receptor and therapeutic uses thereof - Google Patents

Modulators of the cx3cr1 receptor and therapeutic uses thereof Download PDF

Info

Publication number
WO2010079063A3
WO2010079063A3 PCT/EP2009/067325 EP2009067325W WO2010079063A3 WO 2010079063 A3 WO2010079063 A3 WO 2010079063A3 EP 2009067325 W EP2009067325 W EP 2009067325W WO 2010079063 A3 WO2010079063 A3 WO 2010079063A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
modulators
cx3cr1 receptor
therapeutic uses
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/067325
Other languages
French (fr)
Other versions
WO2010079063A2 (en
Inventor
Guy Gorochov
Karim Dorgham
Christophe Combadiere
Philippe Deterre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie
Original Assignee
Universite Pierre et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie filed Critical Universite Pierre et Marie Curie
Priority to CA2746976A priority Critical patent/CA2746976A1/en
Priority to US13/140,615 priority patent/US20120141538A1/en
Priority to JP2011541413A priority patent/JP2012511921A/en
Priority to EP09801438A priority patent/EP2358738A2/en
Publication of WO2010079063A2 publication Critical patent/WO2010079063A2/en
Anticipated expiration legal-status Critical
Publication of WO2010079063A3 publication Critical patent/WO2010079063A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.
PCT/EP2009/067325 2008-12-17 2009-12-16 Modulators of the cx3cr1 receptor and therapeutic uses thereof Ceased WO2010079063A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2746976A CA2746976A1 (en) 2008-12-17 2009-12-16 Modulators of the cx3cr1 receptor and therapeutic uses thereof
US13/140,615 US20120141538A1 (en) 2008-12-17 2009-12-16 Modulators of the cx3cri receptor and therapeutic uses thereof
JP2011541413A JP2012511921A (en) 2008-12-17 2009-12-16 CX3CR1 receptor modulator and therapeutic use thereof
EP09801438A EP2358738A2 (en) 2008-12-17 2009-12-16 Modulators of the cx3cr1 receptor and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055683 WO2010070394A1 (en) 2008-12-17 2008-12-17 Modulators of the cx3cr1 receptor and therapeutic uses thereof
IBPCT/IB2008/055683 2008-12-17

Publications (2)

Publication Number Publication Date
WO2010079063A2 WO2010079063A2 (en) 2010-07-15
WO2010079063A3 true WO2010079063A3 (en) 2013-10-24

Family

ID=41060071

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2008/055683 Ceased WO2010070394A1 (en) 2008-12-17 2008-12-17 Modulators of the cx3cr1 receptor and therapeutic uses thereof
PCT/EP2009/067325 Ceased WO2010079063A2 (en) 2008-12-17 2009-12-16 Modulators of the cx3cr1 receptor and therapeutic uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/055683 Ceased WO2010070394A1 (en) 2008-12-17 2008-12-17 Modulators of the cx3cr1 receptor and therapeutic uses thereof

Country Status (5)

Country Link
US (1) US20120141538A1 (en)
EP (1) EP2358738A2 (en)
JP (1) JP2012511921A (en)
CA (1) CA2746976A1 (en)
WO (2) WO2010070394A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
PH12021553014A1 (en) 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
EP3035970A1 (en) 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
CN103976941B (en) * 2014-05-09 2015-06-03 青岛大学 Hydrogel based on aptamer linking and preparation method and application thereof
US11053297B2 (en) * 2015-10-30 2021-07-06 La Jolla Institute For Allergy And Immunology Monocyte modulation and control of tumor metastasis
JP2022049718A (en) * 2019-02-05 2022-03-30 アステラス製薬株式会社 Treatment of retinal degenerative disease by introduction of cx3cl1 gene using adeno-associated virus
US20220205980A1 (en) * 2019-04-23 2022-06-30 Eisai R&D Management Co., Ltd. Biomarker for rheumatoid arthritis treatment
CN114206944A (en) * 2019-07-12 2022-03-18 哥本哈根大学 Fusion toxin proteins for treating diseases associated with CMV infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055207A1 (en) * 1999-03-16 2000-09-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health A novel chimeric protein for prevention and treatment of hiv infection
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
WO2002076990A1 (en) * 2001-03-27 2002-10-03 Astrazeneca Ab Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
EP1734367A1 (en) * 2005-06-14 2006-12-20 Cellzome Ag Process for the identification of novel enzyme interacting compounds
WO2008003327A2 (en) * 2006-07-03 2008-01-10 Inagen Aps Immunotoxins for the treatment of diseases related to cmv infection
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7492291A (en) * 1990-02-26 1991-09-18 Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
EP0804486B1 (en) * 1992-11-27 2008-10-01 Laboratoires Serono SA Granulocyte chemotactic protein
CA2430082A1 (en) * 2000-11-29 2002-06-06 Lynkeus Biotech Gmbh Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
DK2135949T3 (en) * 2006-02-14 2013-02-04 Noxxon Pharma Ag MCP-1 Binding Nucleic Acids

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055207A1 (en) * 1999-03-16 2000-09-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health A novel chimeric protein for prevention and treatment of hiv infection
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
WO2002076990A1 (en) * 2001-03-27 2002-10-03 Astrazeneca Ab Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
EP1734367A1 (en) * 2005-06-14 2006-12-20 Cellzome Ag Process for the identification of novel enzyme interacting compounds
WO2008003327A2 (en) * 2006-07-03 2008-01-10 Inagen Aps Immunotoxins for the treatment of diseases related to cmv infection
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COMBADIERE C ET AL.: "Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 37, 11 September 1998 (1998-09-11), AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, pages 23799 - 23804, XP002158116, ISSN: 0021-9258, DOI: 10.1074/JBC.273.37.23799 *
DELALEU N ET AL.: "Inhibition of experimental Sjogren's syndrome through immunization with Hsp60 and its peptide amino acids 437-460", ARTHRITIS & RHEUMATISM, vol. 58, no. 8, August 2008 (2008-08-01), JOHN WILEY & SONS, INC, US, pages 2318 - 2328, XP009122944, ISSN: 0004-3591, [retrieved on 20080730], DOI: 10.1002/ART.23656 *
ELICES M J ET AL.: "Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature", JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 1, January 1994 (1994-01-01), AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, pages 405 - 416, XP009052418, ISSN: 0021-9738, DOI: 10.1172/JCI116975 *
INOUE A ET AL.: "Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice", ARTHRITIS & RHEUMATISM, vol. 52, no. 5, May 2005 (2005-05-01), JOHN WILEY & SONS, INC, US, pages 1522 - 1533, XP009122926, ISSN: 0004-3591, DOI: 10.1002/ART.21007 *

Also Published As

Publication number Publication date
WO2010070394A1 (en) 2010-06-24
JP2012511921A (en) 2012-05-31
US20120141538A1 (en) 2012-06-07
CA2746976A1 (en) 2010-07-15
WO2010079063A2 (en) 2010-07-15
EP2358738A2 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
WO2010079063A3 (en) Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
IL202648B (en) Aqueous pharmaceutical compositions comprising vla-4 binding antibodies for treatment of inflammatory, immune and autoimmune disorders
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
EA200970810A1 (en) MODIFIED ACTIVIN RECEPTOR POLYPEPTIDES AND THEIR APPLICATION
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2008105886A3 (en) HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MX2010008688A (en) Engineered anti-tslpr antibodies.
MA32190B1 (en) Antibodies to angiopoietin 1 and angiopoietin 2 and their use
WO2012076293A9 (en) Formulations comprising polysiloxanes having nitrogen-containing groups
UA112514C2 (en) C5aR ANTAGONISTS
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
HUE050319T2 (en) Compositions and methods for treating alcohol-related disorders, pain and other diseases
WO2007076070A3 (en) Modulators of muscarinic receptors
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2008021375A3 (en) Modulators of muscarinic receptors
MX2009007337A (en) 5-pyridinone substituted indazoles.
WO2007100664A3 (en) Modulators of muscarinic receptors
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801438

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009801438

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2746976

Country of ref document: CA

Ref document number: 2011541413

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13140615

Country of ref document: US